Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jesus G,Berdeja

第一单位： Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology PLLC, Nashville, TN.

作者： Jesus G,Berdeja ^[1] ; Jacob P,Laubach ^[2] ; Joshua,Richter ^[3] ; Steve,Stricker ^[4] ; Andrew,Spencer ^[5] ; Paul G,Richardson ^[2] ; Ajai,Chari ^[6]

作者单位： Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology PLLC, Nashville, TN. ^[1] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. ^[2] Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY. ^[3] Secura Bio, Las Vegas, NV. ^[4] Alfred Hospital - Monash University, Melbourne, Australia. ^[5] Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY. Electronic address: ajai.chari@mountsinai.org. ^[6]

关键词 Histone deacetylase inhibitors Refractory Relapsed

主题词组蛋白脱乙酰基酶抑制剂(Histone Deacetylase Inhibitors);人类(Humans);多发性骨髓瘤(Multiple Myeloma)

DOI 10.1016/j.clml.2021.06.020

PMID 34340951

发布时间 2022-02-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交